. 2014 Sep 16;2014:146170. doi: 10.1155/2014/146170

Table 2.

MicroRNAs associated with PCa prognosis.

References	Sample type	Clinical parameters	miRs deregulated	miRs selected as candidate biomarkers
Taylor et al. (2010) [24]	113 PCa tissues 28 normal tissues	Large screening study		Taylor et al. 10.1016/j.ccr.2010.05.026

Martens-Uzunova et al. (2012) [44]	102 PCa tissues and normal adjacent tissues	High risk biochemical recurrence	12 upregulated 13 downregulated	miR-19a, miR-130a, miR-20a/106/93	↑
Martens-Uzunova et al. (2012) [44]	102 PCa tissues and normal adjacent tissues	High risk biochemical recurrence	12 upregulated 13 downregulated	miR-27, miR-143, miR-221/222	↓

Tong et al. (2009) [53]	40 FFPE prostatectomy Specimens (20 without early BCR 20 with early BCR)	Biochemical recurrence	2 upregulated 4 downregulated	miR-135, miR-194 (40% of case)	↑
Tong et al. (2009) [53]		Biochemical recurrence	2 upregulated 4 downregulated	miR-145, miR-221, miR-222	↓

Schaefer et al. (2010) [54]	76 PCa and adjacent normal tissues	Biochemical recurrence	5 upregulated 10 downregulated	miR-96	↑

Hulf et al. (2013) [55]	149 PCa and 30 matched normal tissues	Biochemical recurrence	1 downregulated	miR-205	↓

Schubert et al. (2013) [62]	BCR tissues and disease-free tissues	Biochemical recurrence	2 downregulated	let-7b and let-7c	↓

Leite et al. (2011) [66]	21 frozen BCR tissues 28 frozen disease-free tissues	Biochemical recurrence	4 upregulated	miR-100	↑

Karatas et al. (2014) [72]	82 PCa tissues (41 BCR and 41 disease-free)	Biochemical recurrence	3 downregulated	miR-1, miR-133b	↓

Selth et al. (2013) [102]	Serum samples from PCa patients (BCR = 8) disease-free = 8)	Biochemical recurrence	3 upregulated	miR-194 miR-146-3p	↑

Shen et al. (2012) [87]	Plasma samples from PCa (n = 82)	Castration resistance	2 upregulated	miR-21, miR-145	↑

Jalava et al. (2012) [90]	28 primary PCa tissues 14 CRPC tissues 12 BPH tissues	Castration resistance	4 upregulated 3 downregulated	miR-32, miR-148a, miR-590-5p, miR-21	↑
Jalava et al. (2012) [90]	28 primary PCa tissues 14 CRPC tissues 12 BPH tissues	Castration resistance	4 upregulated 3 downregulated	miR-99a, miR-99b, miR-221	↓

Peng et al. (2011) [94]	6 primary PCa tissues 7 bone metastatic tissues	Metastasis	5 downregulated	miR-508-5p, miR-143, miR-145, miR-33a, miR-100	↓

Saini et al. (2011) [95]	36 PCa tissues 8 metastatic tissues 8 normal tissues	Metastasis	1 downregulated	miR-203	↓

Mitchell et al. (2008) [19]	Serum samples from metastatic PCa (n = 25) and age-matched HD (n = 25)	Metastasis	6 deregulated	miR-141	↑

Brase et al. (2011) [100]	Serum samples from localized PCa (n = 14) and metastatic PCa (n = 7)	Metastasis	5 upregulated	miR-141, miR-375	↑

Bryant et al. (2012) [48]	Serum samples from PCa (n = 72) and metastatic PCa (n = 47) Plasma samples from PCa (n = 55) and metastatic PCa (n = 24)	Metastasis	2 upregulated	miR-141 and miR-375	↑

Nguyen et al. (2013) [103]	Serum samples from localized PCa (n = 58) and metastatic CRPC (n = 26)	Castration resistance	3 upregulated 1 downregulated	miR-141, miR-375, miR-378∗	↑
Nguyen et al. (2013) [103]		Castration resistance	3 upregulated 1 downregulated	miR-409-3p	↓

Zhang et al. (2011) [88]	Serum samples from localized PCa (n = 20), ADPC (n = 20), CRPC DTX treated (n = 10) and BPH (n = 6)	Castration resistance	1 upregulated	miR-21	↑

FFPE: formalin-fixed, paraffin-embedded, BCR: biochemical recurrence, Pca: prostate cancer, CRPC: castration resistant prostate cancer, BPH: benign prostatic hyperplasia, HD: healthy donors.